Skip to main content
2025 STS Annual Meeting Main banner

PreCon - Lung Cancer

Part III: Interactive Tumor Board

Thursday, January 23, 2025
4:35pm - 5:15pm PT
Location: 408B

Ticket (red)

    Moderator(s)

  • Mara Antonoff, MD (she/her/hers)

    Associate Professor, Program Director of Education
    UT MD Anderson Cancer Center
    Houston, Texas, United States

    Disclosure(s): BMS, AZ, Merck, Ethicon: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)

  • Kiran Lagisetty, MD

    Assistant Professor of Surgery
    University of Michigan
    Ann Arbor, Michigan, United States

    Disclosure(s): AtriCure: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

    • Panelist(s)

  • Ashley Prosper, MD (she/her/hers)

    Associate Professor of Radiology, Section Chief of Cardiothoracic Imaging
    UCLA
    Los Angeles, California, United States

    Disclosure(s): Canon: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, July 1, 2024); MedQIA: Consultant (Ongoing)

  • Scott Oh, DO (he/him/his)

    Professor of Clinical Medicine / Interventional Pulmonology
    UCLA, California, United States

    Disclosure(s): No relevant disclosure to display

  • Percy Lee, MD (he/him/his)

    Professor & Vice-Chair, Medical Director of Orange County and Coastal Regions
    City of Hope National Medical Center
    Irvine, California, United States

    Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Genentech: Consultant (Ongoing); ImmuneSensor: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Johnson & Johnson: Advisory Board (Ongoing), Consultant (Ongoing); Roche: Consultant (Ongoing); RTOG Foundation: Consultant (Terminated); Varian: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

  • David Cooke, MD (he/him/his)

    Professor & Chief, Division of General Thoracic Surgery; Physician in Chief Comprehensive Cancer Center
    University of California, Davis Health
    Sacramento, California, United States

    Disclosure(s): Bristol Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Intuitive Surgical: In kind education support; Food (Ongoing); Oxford University Press: Royalties (Ongoing)

  • Karen Reckamp, MD (she/her/hers)

    Director, Division of Medical Oncology
    Cedars Sinai
    Los Angeles, California, United States

    Disclosure(s): AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis, Novocure: Consultant (Terminated, September 11, 2024); Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen: research funding to institution (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Disclosure(s):
Mara B. Antonoff, MD: BMS, AZ, Merck, Ethicon: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)
Kiran Lagisetty, MD: AtriCure: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
Ashley E. Prosper, MD: Canon: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, July 1, 2024); MedQIA: Consultant (Ongoing)
Scott Oh: No relevant disclosure to display
Percy Lee, MD: AstraZeneca: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Genentech: Consultant (Ongoing); ImmuneSensor: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Johnson & Johnson: Advisory Board (Ongoing), Consultant (Ongoing); Roche: Consultant (Ongoing); RTOG Foundation: Consultant (Terminated); Varian: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
David Tom Cooke, MD: Bristol Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Intuitive Surgical: In kind education support; Food (Ongoing); Oxford University Press: Royalties (Ongoing)
Karen Reckamp, MD: AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis, Novocure: Consultant (Terminated, September 11, 2024); Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen: research funding to institution (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Presentations:

  • 4:35pm - 4:40pm PT
    Introduction

    Invited Speaker: Kiran Lagisetty, MD – University of Michigan

  • 4:40pm - 4:42pm PT
    Case 1
  • 4:42pm - 4:50pm PT
    Discussion
  • 4:50pm - 4:52pm PT
    Case 2
  • 4:52pm - 5:00pm PT
    Discussion
  • 5:00pm - 5:02pm PT
    Case 3
  • 5:02pm - 5:10pm PT
    Discussion
  • 5:10pm - 5:15pm PT
    Closing Remarks

    Invited Speaker: John D. Mitchell, MD – University of Colorado School of Medicine